<DOC>
	<DOCNO>NCT02298010</DOCNO>
	<brief_summary>The pattern lymph node metastasis gastric cancer geographic lymph nose station relation metastasis survival analyze retrospective review medical record enrol CLASSIC trial ( NCT00411229 ) compare adjuvant chemotherapy adjuvant therapy radical gastrectomy extend lymphadenectomy .</brief_summary>
	<brief_title>Lymph Node Metastasis Extended Lymphadenectomy Gastric Cancer From CLASSIC Trial</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Criteria previous CLASSIC trial : To eligible inclusion , patient must fulfill follow criterion : Ambulatory male female , age ≥18 year . Karnofsky performance status ≥70 % . Histologically confirm gastric adenocarcinoma , stag pathologically , AJCC/UICC stage II ( T2N1 , T1N2 , T3N0 ) , IIIa ( T3N1 , T2N2 , T4N0 ) , IIIb ( T3N2 ) . At least 15 examined lymph node require ensure adequate TNM classification ) Patients underwent curative D2 lymphadenectomy resection gastric cancer macroscopic microscopic evidence remain tumor , randomize either study arm within 6 week surgery . Give write informed consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice . Patients fulfill follow criterion exclude : Serious concomitant medical illness would limit life expectancy &lt; 5 year . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Postmenopausal woman must amenorrheic least 12 month consider nonchild bear potential . Sexually active male female ( childbearing potential ) unwilling practice contraception study . Any evidence metastatic disease ( include presence tumor cell ascites ) . Previous cytotoxic chemotherapy , radiotherapy immunotherapy except corticosteroid , currently treat gastric cancer . History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . History uncontrolled seizure , central nervous system disorder psychiatric disability judge Investigator clinically significant precluding inform consent interfere compliance oral drug intake . Clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , New York Heart Association ( NYHA ) grade II great congestive heart failure serious cardiac arrhythmia require medication myocardial infarction within last 12 month . Lack physical integrity upper gastrointestinal tract malabsorption syndrome likely influence absorption capecitabine , inability take oral medication . Known peripheral neuropathy ≥ CTCAEv3 grade 1 . Absence deep tendon reflex ( DTRs ) sole neurologic abnormality render patient ineligible . Organ allograft require immunosuppressive therapy . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Moderate severe renal impairment [ creatinine clearance equal 50 ml/min ( calculate accord Cockroft Gault ) ] , serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . Any follow laboratory value : Absolute neutrophil count ( ANC ) &lt; 1.5 x 10^9/L Platelet count &lt; 100 x 10^9/L Total bilirubin &gt; 1.5 x ULN ALAT , ASAT &gt; 2.5 x ULN Alkaline phosphatase &gt; 2.5 x ULN . Prior unanticipated severe reaction fluoropyrimidine therapy ( without document DPD deficiency ) patient Kknown dihydropyrimidine dehydrogenase ( DPD ) deficiency . Hypersensitivity platinum compound component study medication . Received investigational drug agent/procedure , i.e . participation another trial , within 4 week randomization . Blood transfusion growth factor aid hematologic recovery within 2 week prior study treatment start . Requirement concurrent use antiviral agent sorivudine ( antiviral ) chemically related analogue , brivudine . Unwilling unable comply protocol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>